Shares of Adaptimmune Therapeutics PLC – (NASDAQ:ADAP) were down 3.4% during mid-day trading on Monday . The company traded as low as $7.09 and last traded at $7.12, with a volume of 50,729 shares trading hands. The stock had previously closed at $7.37.

Separately, Zacks Investment Research raised shares of Adaptimmune Therapeutics PLC – from a “hold” rating to a “buy” rating and set a $9.75 price target on the stock in a report on Tuesday, July 12th. One equities research analyst has rated the stock with a sell rating and five have given a buy rating to the stock. The company presently has an average rating of “Buy” and a consensus target price of $15.94.

The stock has a 50-day moving average price of $7.40 and a 200-day moving average price of $8.54. The firm’s market cap is $491.96 million.

Adaptimmune Therapeutics PLC – (NASDAQ:ADAP) last released its quarterly earnings data on Monday, August 8th. The company reported ($0.05) earnings per share for the quarter, beating the consensus estimate of ($0.21) by $0.16. On average, analysts expect that Adaptimmune Therapeutics PLC – will post ($1.16) EPS for the current year.

A number of institutional investors have recently made changes to their positions in ADAP. Glenmede Trust Co. NA increased its position in shares of Adaptimmune Therapeutics PLC – by 574.9% in the second quarter. Glenmede Trust Co. NA now owns 20,923 shares of the company’s stock worth $170,000 after buying an additional 17,823 shares in the last quarter. Springbok Capital Management LLC purchased a new position in shares of Adaptimmune Therapeutics PLC – during the first quarter worth approximately $202,000. Zurcher Kantonalbank Zurich Cantonalbank increased its position in shares of Adaptimmune Therapeutics PLC – by 3.3% in the second quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 108,995 shares of the company’s stock worth $888,000 after buying an additional 3,519 shares in the last quarter. Renaissance Technologies LLC increased its position in shares of Adaptimmune Therapeutics PLC – by 286.3% in the first quarter. Renaissance Technologies LLC now owns 113,200 shares of the company’s stock worth $920,000 after buying an additional 83,900 shares in the last quarter. Finally, New Leaf Venture Partners L.L.C. purchased a new position in shares of Adaptimmune Therapeutics PLC – during the second quarter worth approximately $1,035,000.

About Adaptimmune Therapeutics PLC –

Adaptimmune Therapeutics plc is a clinical-stage biopharmaceutical company. The Company is focused on cancer immunotherapy products based on its T-cell receptor (TCR) platform. The Company has developed a platform that enables it to identify cancer targets in the form of peptides, which are short sequences of amino acids, find and genetically engineer TCRs, and produce TCR therapeutic candidates for administration to patients.

5 Day Chart for NASDAQ:ADAP

Receive News & Ratings for Adaptimmune Therapeutics PLC - Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Adaptimmune Therapeutics PLC - and related companies with MarketBeat.com's FREE daily email newsletter.